Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
- DOI
- 10.1016/s0140-6736(25)02165-8
- Published
- 2025-12
- Container
- The Lancet
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-25-02165-8,
title = {Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial},
author = {Deborah B Horn and Donna H Ryan and Sanja Giljanovic Kis and Breno Alves and Yiming Mu and Sin Gon Kim and Jens Aberle and Stephen C Bain and Sheryl Allen and Elizabeth Sarker and Qiwei Wu and Adam Stefanski and Irina Jouravskaya},
year = {2025},
journal = {The Lancet},
doi = {10.1016/s0140-6736(25)02165-8},
url = {https://doi.org/10.1016/s0140-6736(25)02165-8}
}RIS
TY - JOUR TI - Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial AU - Deborah B Horn AU - Donna H Ryan AU - Sanja Giljanovic Kis AU - Breno Alves AU - Yiming Mu AU - Sin Gon Kim AU - Jens Aberle AU - Stephen C Bain AU - Sheryl Allen AU - Elizabeth Sarker AU - Qiwei Wu AU - Adam Stefanski AU - Irina Jouravskaya PY - 2025 JO - The Lancet DO - 10.1016/s0140-6736(25)02165-8 UR - https://doi.org/10.1016/s0140-6736(25)02165-8 ER -
APA
Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., Wu, Q., Stefanski, A., & Jouravskaya, I. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(25)02165-8
Source records
- crossref · retrieved 2026-09-27T13:19:06.114Z